Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00320151
Other study ID # Blood Collection Protocol
Secondary ID
Status Completed
Phase N/A
First received April 27, 2006
Last updated May 23, 2017
Start date April 2006
Est. completion date August 2015

Study information

Verified date May 2017
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This protocol is designed to gather a small amount of blood from patients seen in the New York Presbyterian Hospital-Weill Cornell Medical Center Pulmonary, Critical Care unit, and 5 West floor (Pulmonary Floor) for clinical care associated with chronic lung disease. This protocol will also survey medical records of patients with chronic lung disease, in order to study the clinical characteristics of these individuals. Investigators aim to understand the genetics of chronic lung diseases, and will use the serum and DNA from this blood to perform various genotyping studies such as such as genomic/gene expression studies of individuals with chronic lung diseases


Description:

This protocol is designed to gather a small amount of blood from patients seen in the New York Presbyterian Hospital-Weill Cornell Medical Center Pulmonary, Critical Care unit, and 5 West floor (Pulmonary Floor) for clinical care associated with chronic lung disease. This protocol will also survey medical records of patients with chronic lung disease, in order to study the clinical characteristics of these individuals. Investigators aim to understand the genetics of chronic lung diseases, and will use the serum and DNA from this blood to perform various genotyping studies such as such as genomic/gene expression studies of individuals with chronic lung diseases.

General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) patients with diseases of organs with known association with lung disease.

The following studies will be conducted on blood specimens: genomic DNA will be extracted; promoter sequences for antioxidant-related genes will be obtained by PCR and sequenced. The goal is to find single nucleotide polymorphisms (SNP) to see if they correlate with lung disease. DNA samples and blood specimens will be coded. Samples could potentially be traced back to the patient. However, every effort will be made to keep the patient's identity confidential per HIPAA regulations.

The study does not aim to create a blood bank. Rather, the blood samples will be used for DNA extraction only. Serum will be stored for future studies, to look at levels of proteins.


Recruitment information / eligibility

Status Completed
Enrollment 3087
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Must provide informed consent

- Males and females, age 18 years and older

- Lung disease proven by at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) diseases of organs with known association with lung disease

Exclusion Criteria:

- Drug and/or alcohol abuse within the past six months

- Females who are pregnant or nursing

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Weill Medical College of Cornell University New York New York

Sponsors (1)

Lead Sponsor Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT00367913 - Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease Phase 4
Completed NCT02146235 - Music Therapy in the Treatment of Chronic Obstructive Pulmonary Disease N/A
Not yet recruiting NCT05452148 - Specific Genotypes/Phenotypes of Pneumocystis Jirovecii in Solid Organ Transplant Recipients: Potential Involvement of Mycophenolic Acid
Not yet recruiting NCT05847894 - Assisting Pulmonary Disease Diagnosis With Ophthalmic Artificial Intelligence Technology
Completed NCT00719784 - Vibration Response Imaging in the Diagnosis of Pulmonary Disease N/A
Completed NCT03740646 - Pneumocystis Primary Infection in Non-immunosuppressed Infants
Completed NCT00284141 - Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Phase 2
Completed NCT00293514 - TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM) Phase 3
Completed NCT02002351 - Prospective Study on Rehabilitation Patients With Pulmonary Hypertension and Other Pulmonary Diseases N/A
Recruiting NCT01592513 - Effect of BIS Monitoring on Propofol Usage During Elective Bronchoscopy N/A
Completed NCT00886353 - Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2) Phase 1
Completed NCT00395330 - Airways Dysfunction Following WTC Dust Exposure N/A
Not yet recruiting NCT00248391 - The Influence of Feeding Position on Pulmonary Morbidity in Young Children N/A